JnJ to discontinue Phase 2 Field Study evaluating investigational antiviral for Dengue prevention
Raritan: Johnson & Johnson has announced it is discontinuing the Phase 2 field study (NCT05201794) evaluating the efficacy of investigational antiviral candidate mosnodenvir for the prevention of dengue virus in adults aged 18-65 years.
The decision to discontinue this study is part of a strategic reprioritization of the Company’s Communicable Diseases research and development (R&D) portfolio. No safety issues were identified.
Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete. Study investigators have been notified of the discontinuation. All participants have completed the study per protocol and will be notified of the results once they are ready.
Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies. Results from the Phase 2a human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.
"Johnson & Johnson will continue to support the fight against dengue by sharing study results with the medical community in the future," the Company stated.
